- Anomalies of uterus
- Hormone Replacement Therapy
- Induction of Ovulation
- Male Infertility
- Menstrual Irregularities
- Ovarian Cysts
- Premature Menopause
- Premature Ovarian Failure (POF)
- Removal of fibroids
- Semen Analysis
Contact Us Today!
- Phone: (503) 227-4050
- Fax: (503) 477-7673
Connect With Us
Follow us on FacebookFacebook
What is Femara?
Femara to Induce Ovulation
When the enzyme aromatase is inhibited by the letrozole medication, estrogen levels are suppressed in young women. This results in the brain and pituitary gland increasing the output of FSH (follicle stimulating hormone).
In women that have polycycstic ovary syndrome or anovulation (a problem with ovulation) the increase in FSH hormone can result in development of a mature follicle in the ovary and ovulation of an egg. Doctors call this process induction of ovulation.
Femara to Increase Pregnancy Chances in Ovulating Women
In women that already ovulate on their own, treatment with Femara can result in development of multiple follicles and multiple eggs releasing.
- Release of multiple eggs can increase the chances for pregnancy as compared to release of a single egg with a natural menstrual cycle
- Doctors refer to the process of stimulating ovulation of multiple follicles and eggs as superovulation, or controlled ovarian hyperstimulation.
Femara and Pregnancy – Success Rates Using Femara
Monthly chances for getting pregnant using letrozole are about the same as with using Clomid.
Much will depend on the age of the female and on the status of the fallopian tubes and the male’s sperm quality.
Higher Success for Women Not Ovulating on Their Own
With the following conditions, we can expect approximately 15% per month for a chance to get pregnant with Femara:
- No other fertility issues are present
- The female partner is under 35 years old
- We achieve ovulation with the letrozole in a woman that was not ovulating
Lower Success for Unexplained Fertility in Ovulating Women
When it is being used for unexplained infertility in a woman who ovulates regularly on her own, the expectations for success are significantly lower than that.
Femara has been approved for:
- Treatment of postmenopausal women with hormone
receptor-positive or unknown advanced breast cancer that was progressing after anti-estrogen therapy—in 1997
- First-line treatment of postmenopausal women with hormone receptor-positive or unknown locally advanced or metastatic breast cancer—in 2001
- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy—in 2004